NattoPharma builds patent portfolio for MenaQ7 ingredient
The patents are as follows:
- Israel: On July 31, 2017, patent #238199 “Process for preparation of MK-7 type of Vitamin K2” was granted.
- United States: On August 28, 2017, Notice of Allowance for patent #14/435,260 “Process for preparation of MK-7 type vitamin K2” was issued.
- Australia: On July 5, 2017, Notice of Acceptance (NoA) was issued for patent #2013330517 “process for preparation of MK-7 type of vitamin K2”. This NoA was published on July 20.
“This unique patented process results in the world’s only truly all-trans synthetic Vitamin K2 as MK-7,” says William Sommer, NattoPharma’s Vice President of Global Development & Regulatory. Sommer said the high quality of the resulting ingredient has resulted in its being chosen as the material for two clinical studies “sponsored by the traditional medical community.”
“These studies are evidence that the medical community recognizes the difference a vitamin can make for human health, and in selecting MenaQ7
